Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Antibodies that block programmed death 1 (PD-1) protein improve survival in patients with advanced non-small-cell lung cancer (NSCLC) but have not been tested in resectable NSCLC, a condition in which little progress has been made during the past decade. METHODS: In this pilot study, we administered two preoperative doses of PD-1 inhibitor nivolumab in adults with untreated, surgically resectable early (stage I, II, or IIIA) NSCLC. Nivolumab (at a dose of 3 mg per kilogram of body weight) was administered intravenously every 2 weeks, with surgery planned approximately 4 weeks after the first dose. The primary end points of the study were safety and feasibility. We also evaluated the tumor pathological response, expression of programmed death ligand 1 (PD-L1), mutational burden, and mutation-associated, neoantigen-specific T-cell responses. RESULTS: Neoadjuvant nivolumab had an acceptable side-effect profile and was not associated with delays in surgery. Of the 21 tumors that were removed, 20 were completely resected. A major pathological response occurred in 9 of 20 resected tumors (45%). Responses occurred in both PD-L1-positive and PD-L1-negative tumors. There was a significant correlation between the pathological response and the pretreatment tumor mutational burden. The number of T-cell clones that were found in both the tumor and peripheral blood increased systemically after PD-1 blockade in eight of nine patients who were evaluated. Mutation-associated, neoantigen-specific T-cell clones from a primary tumor with a complete response on pathological assessment rapidly expanded in peripheral blood at 2 to 4 weeks after treatment; some of these clones were not detected before the administration of nivolumab. CONCLUSIONS: Neoadjuvant nivolumab was associated with few side effects, did not delay surgery, and induced a major pathological response in 45% of resected tumors. The tumor mutational burden was predictive of the pathological response to PD-1 blockade. Treatment induced expansion of mutation-associated, neoantigen-specific T-cell clones in peripheral blood. (Funded by Cancer Research Institute-Stand Up 2 Cancer and others; ClinicalTrials.gov number, NCT02259621 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous studies examining the clinical activity of single agent anti-PD-1/PD-L1 therapies in the neoadjuvant setting have reported MPR rates between 19% and 45% in patients with resectable NSCLC14–16.”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“some studies have found that high TCR diversity in peripheral blood and tumors prior to ICI therapy is predictive of effective treatment, others have pointed to ICI therapy-associated increases in TCR clonality, that is, enrichment of T cells with the same TCRs, as a sign of effective therapy (150, 157-161).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [160]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Immune checkpoint blockade (ICB), especially targeting the inhibitory receptor programmed cell death 1 (PD-1) expressed on CD8+ T cells, is a highly effective immunotherapy for various cancers.”
From Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer (2025) · cites this paper as [2]
Experimental — accuracy not yet measuredIn the citing paper
“Similarly, studies of neoadjuvant immunotherapy in patients with resectable NSCLC reported responses irrespective of PD-L114,21,”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [14]
In the citing paper
“Clinical trials with ICT in the neoadjuvant setting have now demonstrated clinical benefit in multiple tumor types, including melanoma (173, 174), Merkel cell carcinoma (175), NSCLC (176), MMRdeficient colorectal cancer (177), urothelial carcinoma (21, 178), and breast cancer (179-181).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [176]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationToxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Self-citationPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationMismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Self-citationPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Cited by
Items 701–800 of 1,000
Kwiecień, I., Skirecki, T., Polubiec-Kownacka, M., Raniszewska, A., & Domagala-Kulawik, J. J. (2019) · Cancers · doi:10.3390/cancers11040567 · Cited by 24
“In the first study of nivolumab in the neoadjuvant therapy it was shown to be effective in tumors with a high pre-treatment mutational burden [45], however in the recently published results of combination therapy: nivolumab plus ipilimumab better results were achieved in non-SCC [43].”
ResultCurrent Immunotherapy Practices in Melanoma
Rothermel, L. D., Sarnaik, A. A., Khushalani, N. I., & Sondak, V. K. (2019) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2019.02.001 · Cited by 23
Review and perspective on adjuvant and neoadjuvant immunotherapies in NSCLC
Yi, C., He, Y., Xia, H., Zhang, H., & Zhang, P. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s218321 · Cited by 24
“As for neoadjuvant immunotherapies, MPR has been used as a primary or second endpoint in some researches.(30) Above experience about”
BackgroundMethodInfluentialBrabo, E. P., Moraes, A. B., & Neto, L. V. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01306-5 · Cited by 25
“The immune infiltration of the tumor bed after ICI therapy may be misdiagnosed as a progressive disease by conventional imaging [27].”
BackgroundSong, Y., Yan, S., Fan, W., Zhang, M., Liu, W., Lu, H., Cao, M., Hao, C., Chen, L., Tian, F., et al. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00550 · Cited by 26
“Immunotherapy has shown a considerable clinical success in the treatment response of many LUAD patients; however, when provided with the same immunotherapeutic intervention, little or no clinical benefit is unsatisfactorily found in the many more patients (Forde et al., 2018; Passiglia et al., 2018; Almutairi et al.,…”
BackgroundSurgery after neoadjuvant immunotherapy in patients with resectable non-small cell lung cancer
Huynh, C., Walsh, L. A., & Spicer, J. D. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-509 · Cited by 25
“study did not show a strong correlation between PD-L1 status and MPR, it did reveal a higher TMB with tumors achieving MPR compared to those who did not (77).”
BackgroundResultInfluentialHuang, L., Li, L., Zhou, Y., Yang, Z., Wang, M., Gao, Y., Yang, Y., Yang, F., Liu, B., Hong, X., et al. (2020) · Journal of Cancer · doi:10.7150/jca.49213 · Cited by 26
Guo, H., Diao, L., Zhou, X., Chen, J.-N., Zhou, Y., Fang, Q., He, Y., Dziadziuszko, R., Zhou, C., & Hirsch, F. R. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-96 · Cited by 24
“Moreover, the application of ICIs in resected NSCLC patients has also been proved an efficient approach by clinical trials and was promising to decrease postoperative recurrence risks (41,42).”
MethodSelf-citationShiba‐Ishii, A. (2021) · Pathology International · doi:10.1111/pin.13147 · Cited by 25
“On the other hand, although lung adenocarcinoma has historically been identified as a non‐immunogenic disease, trials of neoadjuvant immunotherapy have been conducted for a small number of resectable non‐small cell lung cancers (NSCLCs) treated by anti‐programmed cell death‐1 (anti‐PD‐1) mAb blockade, and promising ef…”
BackgroundImmunotherapeutic Advances for NSCLC
Massafra, M., Passalacqua, M. I., Gebbia, V., Macrì, P., Lazzari, C., Gregorc, V., Buda, C. A., Altavilla, G., & Santarpía, M. (2021) · Biologics · doi:10.2147/btt.s295406 · Cited by 31
Liquid biopsy to identify biomarkers for immunotherapy in hepatocellular carcinoma
Huang, A., Zhang, X., & Zhou, J. (2021) · Biomarker Research · doi:10.1186/s40364-021-00348-y · Cited by 27
“In resectable lung cancer, TMB was predictive of the pathological response in patients with neoadjuvant PD-1 blockade [16].”
BackgroundDahl, O., & Brydøy, M. (2019) · Acta Oncologica · doi:10.1080/0284186x.2018.1555375 · Cited by 24
Advances in Immunotherapy and Implications for Current Practice in Non–Small-Cell Lung Cancer
Steuer, C. E., & Ramalingam, S. S. (2021) · JCO Oncology Practice · doi:10.1200/op.21.00305 · Cited by 24
“Neoadjuvant nivolumab given for two doses in surgically resectable NSCLC was found to induce a 45% pathologic response, with no adverse effects on timing of the surgery.(20) The addition of chemotherapy to IO (atezolizumab) in a similar population raised the pathologic response rate to 57%, but with the added toxiciti…”
BackgroundNovel Strategies for Peptide-Based Vaccines in Hematological Malignancies
Klausen, U., Holmberg, S., Holmström, M. O., Jørgensen, N. G. D., Grauslund, J. H., Svane, I. M., & Andersen, M. H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02264 · Cited by 24
“Another means to enhance the anti-tumor immune response would be to combine JAK2/CALR-vaccines with PD-1 specific mAbs, as treatment with these drugs have been shown to enhance the amount of neo-antigen specific T cells in peripheral blood (75).”
BackgroundAdvances in evidence‐based medicine for immunotherapy of non‐small cell lung cancer
Dong, J., Li, B., Zhou, Q., & Huang, D. (2018) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.12322 · Cited by 25
Sage, A. P., Ng, K. W., Marshall, E. A., Stewart, G. L., Minatel, B. C., Enfield, K. S. S., Martin, S. D., Brown, C. J., Abraham, N., & Lam, W. L. (2020) · Scientific Reports · doi:10.1038/s41598-020-73787-6 · Cited by 23
Popp, F., Capino, I., Bartels, J., Damanakis, A. I., Li, J., Datta, R. R., Löser, H., Zhao, Y., Quaas, A., Lohneis, P., et al. (2021) · Cancers · doi:10.3390/cancers13112689 · Cited by 23
Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC)
Chiu, L., Lin, S., Lo, Y., Kuo, C. S., Yang, C., & Hsu, P. (2021) · Vaccines · doi:10.3390/vaccines9070689 · Cited by 24
“A previous study has shown that neoadjuvant therapy with single nivolumab before surgery had a 45% major pathological response (MPR), acceptable toxicity, and no delay of surgery [79].”
BackgroundResultInfluentialRen, S., Xu, A., Lin, Y., Camidge, D. R., Maïo, M. D., Califano, R., Hida, T., Rossi, A., Guibert, N. M., Zhu, C., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-259 · Cited by 26
“Neoadjuvant nivolumab showed that, of the 20 patients who underwent resection, 9 (45%) achieved major pathological response (MPR) (17).”
BackgroundYang, H., Ma, W., Sun, B., Fan, L., Xu, K., Hall, S. R. R., Al-Hurani, M. F., Schmid, R. A., Peng, R., Hida, T., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-734 · Cited by 25
“(18) enrolled 20 patients with stage I–IIIA NSCLC who received 2 doses of neoadjuvant nivolumab every 2 weeks.”
BackgroundMethodResultInfluentialDykema, A. G., Zhang, B., Woldemeskel, B. A., Garliss, C. C., Rashid, R., Westlake, T., Zhang, L., Zhang, J., Cheung, L. S., Caushi, J. X., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104048 · Cited by 23
Self-citationFang, B., Yu, W., Zeng, H., Li, Y., Chen, S., Zhang, T., Pan, J. G., Wang, B., Wu, J., Jin, S., et al. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03347-6 · Cited by 25
Lin, Y., Zhang, Y., Tuo, Z., Gao, L., Ding, D., Bi, L., Yu, D., Lv, Z., Wang, J., & Chen, X. (2023) · BMC Cancer · doi:10.1186/s12885-023-10763-z · Cited by 28
Treatment Decisions for Resectable Non–Small-Cell Lung Cancer: Balancing Less With More?
O’Reilly, D., Botticella, A., Barry, S. T., Cotter, S., Donington, J. S., Pechoux, C. L., & Naidoo, J. (2023) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_389950 · Cited by 28
Self-citationLi, W., Li, X., Li, X., Li, M., Yang, P., Wang, X., Li, L., & Yang, B. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s229997 · Cited by 22
RetractedLi, Z., Yan, H.-C., Gu, J., Yang, Y., Zhang, M.-K., & Fang, X. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105194 · Cited by 25
Xu, J., Yang, X., Mao, Y., Mei, J., Wang, H., Ding, J., & Hua, D. (2021) · Technology in Cancer Research & Treatment · doi:10.1177/15330338211019442 · Cited by 23
“However, the role of PD-L1 expression as a predictive biomarker remains inconclusive.(12,13) A recent meta-analysis found that PD-L1 expression alone was not an adequate biomarker for patient selection in anti-PD-1/PD-L1 therapy.”
BackgroundSelf-citationTakata, K., Chong, L. C., Ennishi, D., Aoki, T., Li, M. Y., Thakur, A., Healy, S., Viganò, E., Dao, T., Kwon, D., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci145343 · Cited by 26
Classification of lung cancer subtypes on CT images with synthetic pathological priors
Zhu, W., Jin, Y., Ma, G., Chen, G., Egger, J., Zhang, S., & Metaxas, D. (2024) · Medical Image Analysis · doi:10.1016/j.media.2024.103199 · Cited by 24
“In [9], the activity of immune checkpoint inhibitors was found to be different in LUAD than that in LUSC.”
ResultZhao, Y., & Wucherpfennig, K. W. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3296 · Cited by 24
Neoadjuvant immune checkpoint inhibitors for hepatocellular carcinoma
Akula, V., Chen, L., Açıkgöz, Y., Klein, K., Yavuz, B. G., Cevik, L., Demir, T., Manne, A., Şahin, İ., Kaseb, A. O., et al. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00846-4 · Cited by 26
“Immunotherapy has shown promising results in this setting in early-stage melanoma, early-stage mismatch repair-de fi cient colon cancer, and bladder cancer, with major pathologic response (MPR) leading to improved survival outcomes in the post-operative period 9,18 – 21 .”
Wang, X., Li, Y., Li, Y., Wang, X., Song, H., Wang, Y., Huang, C., Mao, C., Wang, L., Zhong, C., et al. (2025) · Science Advances · doi:10.1126/sciadv.adn8402 · Cited by 25
“Despite durable curative effects achieved in immune checkpoint blockade (ICB) treatment for certain malignancies ( 1 – 4 ), few patients with solid tumor benefit from it due to side effect, poor efficacy, and high recurrence ( 5 , 6 ).”
Deutsch, J. S., Scolyer, R. A., Burton, E. M., BUSAM, K. J., Chen, K. Y., Cimino‐Mathews, A., Cottrell, T. R., de Andrea, C. E., Fiset, P., Long, G. V., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.10.018 · Cited by 31
Self-citationUpdates in Local-Regionally Advanced Non–Small Cell Lung Cancer
Tsao, A. S., Jolly, S., & Lee, J. M. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_237839 · Cited by 21
Advances in the Treatment of Stage III Non–Small Cell Lung Cancer
Myall, N. J., & Das, M. S. (2020) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2020.02.008 · Cited by 23
Gutiérrez, V., González, A. C., Gálvez, L., Lizarralde, Y. A., & Rueda‐Domínguez, A. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920984061 · Cited by 23
Shi, H., & Yang, Y. (2021) · Cancer Medicine · doi:10.1002/cam4.3902 · Cited by 22
Cottrell, T. R., Zhang, J., Zhang, B., Kaunitz, G. J., Burman, P., Chan, H. Y., Verde, F., Hooper, J. E., Hammers, H. J., Allaf, M. E., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002642 · Cited by 22
“21 Likewise, clono-type sharing analyses could be confounded by bypassing viral-specific T cells.”
Self-citationSurgical Outcomes After Neoadjuvant Chemoimmunotherapy for Resectable Non-Small Cell Lung Cancer
Hu, Y. W., Ren, S.-Y., Wang, R.-Y., Zeng, C., Li, J., Xiao, P., Wu, F., Yu, F., & Liu, W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.684070 · Cited by 23
“(15) were the first to prospectively investigate the safety and feasibility of neoadjuvant immunotherapy in resectable NSCLC.”
BackgroundInfluentialFurrer, K., Weder, W., Eboulet, E. I., Betticher, D. C., Pless, M., Stupp, R., Krueger, T., Perentes, J. Y., Schmid, R. A., Lardinois, D., et al. (2022) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2022.03.034 · Cited by 26
Yang, L., Zhang, W., Sun, J., Yang, G., Cai, S., Sun, F., Xing, L., & Sun, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1022638 · Cited by 24
Yu, J., Zhikun, G., & Wang, L. (2023) · Life · doi:10.3390/life13051189 · Cited by 24
Hui, Z., Ren, Y., Zhang, D., Chen, Y., Yu, W., Cao, J., Liu, L., Wang, T., Xiao, S., Zheng, L., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00384-x · Cited by 22
“…strategies of multiple cancer types, including NSCLC. Recent clinical trials are exploring the use of ICBs alone or in combination with chemotherapy as a neoadjuvant treatment regimen in patients with NSCLC, inspired by their remarkable clinical ef fi cacy for the treatment of advanced NSCLC 5 – 7 .”
Li, R., Nocera, L., Rose, K. M., Raggi, D., Naidu, S. U., Mercinelli, C., Cigliola, A., Tateo, V., Patanè, D. A., Grass, G. D., et al. (2024) · European Urology Oncology · doi:10.1016/j.euo.2023.12.008 · Cited by 22
Sharma, S., Singh, N., Turk, A. A., Wan, I., Guttikonda, A., Dong, J. L., Zhang, X., & Opyrchal, M. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i13.1815 · Cited by 27
“Immunotherapy with checkpoint inhibitors has provided a significant improvement in cancer treatment, demonstrating high efficacy and manageable side effects in various tumor types[57-62].”
Diagnostic and Predictive Immunohistochemistry for Non–Small Cell Lung Carcinomas
Hung, Y. P., & Sholl, L. M. (2018) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000206 · Cited by 23
Wiegand, S., Wichmann, G., & Dietz, A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00191 · Cited by 22
Programmed Death–Ligand 1 and Vimentin: A Tandem Marker as Prognostic Factor in NSCLC
Ancel, J., Birembaut, P. L., Dewolf, M., Durlach, A., Nawrocki‐Raby, B., Dalstein, V., Delépine, G., Blacher, S., Deslée, G., Gilles, C., et al. (2019) · Cancers · doi:10.3390/cancers11101411 · Cited by 27
Prognostic factors related to postoperative survival in the newly classified clinical T4 lung cancer
Yamanashi, K., Menju, T., Hamaji, M., Tanaka, S., Yutaka, Y., Yamada, Y., Nakajima, D., Ohsumi, A., Aoyama, A., Satō, T., et al. (2019) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezz288 · Cited by 21
McSorley, S. T., Lau, H. Y. N., McIntosh, D., Forshaw, M. J., McMillan, D. C., & Crumley, A. B. C. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-09074-5 · Cited by 26
“Female 97 (29) BMI, kg/m(2) \ 20 16 (5)”
Plasma soluble PD-L1 and STAT3 predict the prognosis in diffuse large B cell lymphoma patients
Fei, Y., Yu, J., Li, Y., Li, L., Zhou, S., Zhang, T., Li, L., Qiu, L., Meng, B., Pan, Y., et al. (2020) · Journal of Cancer · doi:10.7150/jca.47816 · Cited by 23
Clinical Efficacy and Future Prospects of Immunotherapy in Lung Cancer
Kinoshita, T., Terai, H., & Yaguchi, T. (2021) · Life · doi:10.3390/life11101029 · Cited by 24
Chen, X., & Ma, K. (2021) · Current Oncology · doi:10.3390/curroncol28050350 · Cited by 26
“Presently, various neoadjuvant therapy options, such as chemotherapy [5], chemoradiotherapy [6], targeted therapy [7], and immunotherapy [8], are available.”
BackgroundInfluentialZhang, J., Han, X., Lin, L., Chen, J., Wang, F., Ding, Q., Li, H., Wang, L., Wei, J., Wang, Y., et al. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/3583985 · Cited by 26
“PD-1 blockade pembrolizumab has received FDA approval as fi rst-line therapy for advanced NSCLC with > 50% tumor cells expressing PD-L1 [17, 18].”
Self-citationSun, G., Liu, H., Shi, X., Tan, P., Tang, W., Chen, X., Sun, G., Yang, W., Kong, X., Zheng, Z., et al. (2022) · International Journal of Oncology · doi:10.3892/ijo.2022.5364 · Cited by 22
“A clinical study in 2018 reported that the preopera‐ tive use of neoadjuvant PD‐1 related immunotherapy achieved favorable surgical results in patients with lung cancer (21).”
BackgroundTiu, B. C., Strohbehn, I. A., Zhao, S. J., Ouyang, T., Hanna, P. E., Wang, Q., Gupta, S., Leaf, D. E., Reynolds, K. L., & Sise, M. E. (2023) · The Oncologist · doi:10.1093/oncolo/oyad001 · Cited by 24
“73 m2, and (3) if advanced CKD is associated with worse overall survival in patients receiving ICIs.”
BackgroundChen, X., Ding, W., Jiang, Y., Shi, W., Qiu, Y., Zhao, H., & Luo, X. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c12603 · Cited by 22
Multidimensional tumor heterogeneity and its role in therapeutic resistance
Mubin, N., Alnukhali, M., Ahmad, N., Driscoll, J. J., & Ahmad, A. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1794130 · Cited by 24
“These designs have yielded critical insights into adaptive responses to endocrine therapy, immunotherapy, and androgen deprivation, informing treatment schedules explicitly designed to delay resistance (219, 220).”
Immune checkpoint inhibition in muscle-invasive and locally advanced bladder cancer
Gust, K. M., Rebhan, K., Resch, I., Shariat, S. F., & Necchi, A. (2020) · Current Opinion in Urology · doi:10.1097/mou.0000000000000783 · Cited by 20
Novel systemic therapy for hepatocellular carcinoma
Dong, Y., Liu, T., Yau, T. C. C., & Hsu, C. (2020) · Hepatology International · doi:10.1007/s12072-020-10073-7 · Cited by 21
Neoadjuvant immunotherapy in breast cancer: a paradigm shift?
Fountzila, E., & Ignatiadis, M. (2020) · ecancermedicalscience · doi:10.3332/ecancer.2020.1147 · Cited by 21
“In the clinical setting, the administration of two pre-operative doses of a PD-1 inhibitor in patients with resectable non-small cell lung cancer led to an increased number of T-cell clones in the tumour and peripheral blood [25].”
BackgroundZuo, L., Gao, Z., Zhang, M., Wang, X., Gong, J., Jiang, S., & Zhang, Z. (2021) · Annals of Thoracic and Cardiovascular Surgery · doi:10.5761/atcs.oa.21-00143 · Cited by 26
Dai, J., Zhu, X., Li, D., Huang, Y. J., Liu, X., He, W., Duan, L., Zhao, D., Zhu, Y., Chen, C., et al. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-56 · Cited by 22
“Recently, programmed cell death receptor 1 (PD-1) and programmed cell death ligand 1 (PD-L1) checkpoint inhibitors have shown promise in the treatment of locally advanced NSCLC (6,7).”
BackgroundFatalism, Distrust, and Breast Cancer Treatment Refusal in Ghana
Salisu, W. J., Mirlashari, J., Seylani, K., Varaei, S., & Thorne, S. E. (2022) · Canadian Oncology Nursing Journal · doi:10.5737/23688076322198205 · Cited by 20
Zhang, S., Lv, M., Cheng, Y., Wang, S., Li, C., & Qu, X. (2021) · BMC Cancer · doi:10.1186/s12885-021-09065-z · Cited by 23
“Recently, immune checkpoint blockades such as anti-programmed cell-death protein 1(PD1) or programmed cell-death 1 ligand 1 (PD-L1) drugs have been widely used and achieved e cacy in different cancer types (3, 4).”
BackgroundNeoadjuvant Immunotherapy for Hepatocellular Carcinoma
Marron, T. U., Schwartz, M., Corbett, V., & Mérad, M. (2022) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s340935 · Cited by 21
“Additionally, through neoantigen calling and incorporation of T cell receptor (TCR) sequencing, we can resolve the tumor-specific T cells from the conglomerate of tumor-infiltrating T cells, the majority of which are bystanders and not reactive to tumor neoantigen.(18,52) Resolving and phenotyping the pre-existing T c…”
BackgroundLee, B., Mynard, N., Nasar, A., Villena‐Vargas, J., Chow, O. S., Harrison, S. W., Stiles, B. M., Port, J. L., & Altorki, N. K. (2022) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2022.07.017 · Cited by 22
Han, R. F., Zhang, Y., Wang, T., Xiao, H., Luo, Z., Shen, C., Li, J., Zhao, C., Li, L., Zhu, M., et al. (2022) · Cancer Science · doi:10.1111/cas.15778 · Cited by 23
Panian, J. A., Saidian, A., Hakimi, K. N., Ajmera, A., Anderson, W. J., Barata, P. C., Berg, S. A., Signoretti, S., Chang, S. L., D’Andrea, V. D., et al. (2023) · The Oncologist · doi:10.1093/oncolo/oyad166 · Cited by 22
Neoadjuvant SBRT combined with immunotherapy in NSCLC: from mechanisms to therapy
Shi, Y., Ma, X.-Y., He, D., Dong, B., & Qiao, T. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1213222 · Cited by 22
“Numerous clinical trials have confirmed that combining neoadjuvant immunotherapy with chemotherapy can significantly improve the pathological remission rate in patients (16, 18).”
BackgroundZhao, J., Hao, S., Tian, J., Li, Y., & Dan, H. (2023) · Journal of Inflammation Research · doi:10.2147/jir.s424454 · Cited by 20
“Preclinical data show that ICI treatment as a preoperative neoadjuvant therapy has more advantages than postoperative adjuvant therapy because neoadjuvant immunotherapy (IT) can more effectively cause a systemic antitumor immune response by killing tumor cells and releasing antigens before tumor resection, and damage…”
BackgroundNon-immune cell components in tumor microenvironment influencing lung cancer Immunotherapy
Zhang, J., Liu, S., Chen, X., Xu, X., & Xu, F. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115336 · Cited by 22
Self-citationSuay, G., García‐Cañaveras, J. C., Aparisi, F., Lahoz, A., & Juan, Ó. (2023) · Cancers · doi:10.3390/cancers15184433 · Cited by 23
Perioperative immunotherapy for esophageal squamous cell carcinoma: Now and future
Liu, Y. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i34.5020 · Cited by 24
“Neoadjuvant immunotherapy has been explored in various other malignancies, such as lung cancer[41,42], melanoma [43], bladder cancer[44], colon cancer[45], and glioblastoma[46].”
Abed, A., Beasley, A. B., Reid, A. L., Law, N. L., Calapre, L., Millward, M., Lo, J., & Gray, E. S. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.102066 · Cited by 23
“18,19,23,31 The latter is a limitation to be addressed in future studies.”
Schwab, R. M., Schiestl, L. J., Ortolano, L. C., Klecker, P. H., Schmidt, M. W., Almstedt, K., Heimes, A.-S., Brenner, W., Stewen, K., Schmidt, M., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1352975 · Cited by 21
Pan, H., Chen, H., Kong, W., Ning, J., Ge, Z., Tian, Y., Zou, N., Zhu, H., Zhang, J., Tao, Y., et al. (2024) · Clinical Lung Cancer · doi:10.1016/j.cllc.2024.03.008 · Cited by 27
Self-citationAdenosine signaling: Next checkpoint for gastric cancer immunotherapy?
Shi, L., Yang, L., Wu, Z., Xu, W., Song, J. H., & Guan, W. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.07.023 · Cited by 22
Immune checkpoint blockade in solid organ tumours: Choice, dose and predictors of response
Navani, V., Graves, M. C., Bowden, N. A., & van der Westhuizen, A. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14352 · Cited by 21
“a major pathological response in 45% (n = 20) of patients in a NSCLC trial.(100) It has been suggested that nivolumab could be a candidate for dose reduction.”
BackgroundThe Promising Evolution of Targeted Therapeutic Strategies in Cancer
Peters, S., Mok, T. S. K., Passaro, A., & Janne, P. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0124 · Cited by 21
“Moving forward, for patients without a driver oncogene, the role of neoadjuvant and adjuvant immunotherapy needs to be intensively studied (15).”
BackgroundExpert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer
Qiu, B., Cai, K., Chen, C., Chen, J., Chen, K., Chen, Q., Cheng, C., Dai, T., Fan, J., Fan, Z., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-634 · Cited by 22
“Patients with a higher TMB seem to have better MPR in neoadjuvant immunotherapy (9), but the results of the LCMC 3 trial (30) do not support this conclusion.”
BackgroundResultInfluentialYe, N., Bao, M., Xiaoxia, Y., Xie, D., & Jiang, G. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.10.06 · Cited by 20
Hou, X., Shen, Y., Huang, B., Li, Q., Li, S., Jiang, T., Shan, X., Xu, W., Liu, S., Wu, S., et al. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02871-0 · Cited by 22
Fallarino, F., & Blank, C. U. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01222-w · Cited by 27
“The available evidence suggests that low TMB is the only factor that mediates primary resistance to neoadjuvant ICB across different malignancies 4,40–44 , which is supported by the fact that mutations mediating HLA loss or in the JAK–STAT pathway have not been found in early melanoma 45 .”
Liu, L., Li, Y., Li, H., Shang, T., & Liu, L. (2025) · International Journal of Oncology · doi:10.3892/ijo.2025.5824 · Cited by 33
“PD‑1 and PD‑L1 inhibitors are the most extensively studied ICIs in NSCLC. Forde et al (104) demonstrated the potential of neoadjuvant PD‑1 blockade (pembrolizumab) in resectable lung cancer, showing notable tumor regression and increased major histological response rates.”
Navigating the next frontier in biomedicine: breakthroughs and insights in nucleic acid therapeutics
Wu, S., Zhang, Z., Zhao, Z., Cui, C., & Tan, W. (2026) · Chemical Science · doi:10.1039/d5sc06966a · Cited by 22
“160 In parallel with these clinical e ff orts, formulation and delivery technologies are addressing critical limitations.”
Immunotherapy in Lung Cancer: From a Minor God to the Olympus
Russo, A., McCusker, M. G., Scilla, K. A., Arensmeyer, K. E., Mehra, R., Adamo, V., & Rolfo, C. D. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-41008-7_4 · Cited by 20
Feasibility of sleeve lobectomy after neo-adjuvant chemo-immunotherapy in non-small cell lung cancer
Chen, Y., Zhang, L., Yan, B., Zeng, Z., Hui, Z., Zhang, R., Ren, X., & You, J. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-539 · Cited by 20
“It has been reported that neoadjuvant anti-programmed death-1 (PD-1) immunotherapy does not delay surgery and achieves a major pathological response in 83% of patients who undergo tumor resection (1,2).”
BackgroundLei, T., Li, J., Zhong, H., Zhang, H., Jin, Y., Wu, J., Li, L., Xu, B., Song, Q., & Hu, Q. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.680615 · Cited by 20
Zhu, Q., Li, Y., Li, L., Guo, M., Zou, C., Xu, Y., & Yang, Z. (2021) · Bioengineered · doi:10.1080/21655979.2021.2000283 · Cited by 19
Cai, W., Jing, M., Gu, Y., Bei, T., Zhao, X., Chen, S., Wen, J., Gao, J., Wu, C., & Xue, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.984666 · Cited by 19
“CheckMate 159 (NCT02259621), a phase II trial, reported a major pathologic response (MPR) rate of 45% in stage I−III NSCLC with nivolumab (2).”
BackgroundResultA View on Drug Development for Cancer Prevention
Reynolds, A. R., Moschetta, M., Yohannes, A. R., Walcott, F. L., Ashford, M. B., Szűcs, Z., Sarbajna, T., Hadfield, J., Harrison, E., Challis, B., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0776 · Cited by 21
Chan, A., Torelli, S., Cheng, E., Batchelder, R., Waliany, S., Neal, J. W., Witteles, R. M., Nguyen, P. K. P., Cheng, P. P., & Zhu, H. (2023) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-023-01024-0 · Cited by 20
Qu, W., Chen, C., Cai, C., Gong, M., Luo, Q., Song, Y., Yang, M., & Shi, M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1327779 · Cited by 25
The roles of PD-L1 in the various stages of tumor metastasis
He, Y., Zhu, M. Q., Lai, X., Zhang, H., & Jiang, W. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10189-4 · Cited by 22
Liquid biopsy for lung cancer immunotherapy (Review)
Cai, L., & Wang, J. (2019) · Oncology Letters · doi:10.3892/ol.2019.10166 · Cited by 26
“Neoadjuvant nivolumab was indicated to have fewer side effects, to not require any delay in surgery and to induce a major pathological response in 45% of resected tumors (38).”
BackgroundMethodBaba, Y., Yagi, T., Kosumi, K., Okadome, K., Nomoto, D., Eto, K., Hiyoshi, Y., Nagai, Y., Ishimoto, T., Iwatsuki, M., et al. (2019) · British journal of surgery · doi:10.1002/bjs.11301 · Cited by 23
Spectrum and Clinical Activity of PD-1/PD-L1 Inhibitors: Regulatory Approval and Under Development
Oliveira, L. J. D. C., Gongora, A. B. L., & Jardim, D. L. F. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00928-5 · Cited by 20
ZNF300 promotes chemoresistance and aggressive behaviour in non‐small‐cell lung cancer
Yu, S., Ao, Z., Wu, Y. M., Song, L., Zhang, P., Li, X., Liu, M., Qian, P., Zhang, R., Li, X., et al. (2020) · Cell Proliferation · doi:10.1111/cpr.12924 · Cited by 19
Tashiro, T., Imamura, K., Tomita, Y., Tamanoi, D., Takaki, A., Sugahara, K., Sato, R., Saruwatari, K., Sakata, S., Inaba, M., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249705 · Cited by 20
“The fluorescent multiplex immunohistochemistry analysis has been shown to capture multidimensional data related to tissue architecture, spatial distribution of multiple cell phenotypes, and co-expression of signaling [21,22].”
Background
Metadata
- Authors
- Forde, P. M., Chaft, J. E., Smith, K. N., Anagnostou, V., Cottrell, T. R., Hellmann, M. D., Zahurak, M., Yang, S. C., Jones, D. R., Broderick, S., Battafarano, R. J., Velez, M. J., Rekhtman, N., Olah, Z., Naidoo, J., Marrone, K. A., Verde, F., Guo, H., Zhang, J., Caushi, J. X., Chan, H. Y., Sidhom, J.-W., Scharpf, R. B., White, J., Gabrielson, E., Wang, H., Rosner, G. L., Rusch, V., Wolchok, J. D., Merghoub, T., Taube, J. M., Velculescu, V. E., Topalian, S. L., Brahmer, J. R., & Pardoll, D. M.
- Affiliations
- Johns Hopkins University (US)
- Memorial Sloan Kettering Cancer Center (US)
- ORCID
- Forde, Patrick M.
- Chaft, Jamie E.
- Smith, Kellie N.
- Anagnostou, Valsamo
- Cottrell, Tricia R.
- Hellmann, Matthew D.
- Zahurak, Marianna
- Yang, Stephen C.
- Jones, David R.
- Broderick, Stephen
- Velez, Moises J.
- Rekhtman, Natasha
- Naidoo, Jarushka
- Marrone, Kristen A.
- Verde, Franco
- Guo, Haidan
- Zhang, Jiajia
- Caushi, Justina X.
- Sidhom, John-William
- Scharpf, Robert B.
- White, James
- Wang, Hao
- Rosner, Gary L.
- Rusch, Valerie
- Wolchok, Jedd D.
- Merghoub, Taha
- Taube, Janis M.
- Velculescu, Victor E.
- Topalian, Suzanne L.
- Brahmer, Julie R.
- Pardoll, Drew M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-05-24
- Volume
- 378
- Issue
- 21
- Pages
- 1976-1986
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6223617
- OpenAlex
- W2798160602
- Cited by
- 2,099
- References
- 33
- Citations by year
- 2026: 123 · 2025: 181 · 2024: 241 · 2023: 304 · 2022: 304 · 2021: 342 · 2020: 279 · 2019: 214 · 2018: 110
- FWCI
- 89.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- International Association for the Study of Lung Cancer
- LUNGevity Foundation
- MacMillan Foundation
- Lung Cancer Foundation of America
- National Cancer Institute (CA006973, CA121113, CA180950, CA193145, P30 CA006973, P30 CA008748, R01 CA142779, T32 CA193145)
- ECOG-ACRIN
- Commonwealth Foundation
- Dr. Miriam and Sheldon G. Adelson Medical Research Foundation
- Bristol-Myers Squibb
- Bloomberg–Kimmel Institute for Cancer Immunotherapy
- Stand Up To Cancer (SU2C-AACR-DT1012)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- neoadjuvant immunotherapy, anti-PD-1 therapy, nivolumab, resectable non-small cell lung cancer, early-stage lung cancer, pathological response, PD-L1 expression, tumor mutational burden, predictive biomarkers, treatment safety and feasibility
- MeSH terms
- Nivolumab, Adenocarcinoma, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Biopsy, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Pilot Projects, Neoadjuvant Therapy, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.